DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Common Formats for Patient Safety Data Collection

AGENCY: Agency for Healthcare Research and Quality (AHRQ), Department of Health and Human Services (HHS).

ACTION: Notice of availability—new common formats.

SUMMARY: As authorized by the Secretary of HHS, AHRQ coordinates the development of common definitions and reporting formats (Common Formats or formats) for reporting on health care quality and patient safety. The purpose of this notice is to announce the availability of *Common Formats for Surveillance—Hospital Version 1.0* for public review and comment.

DATES: *End of initial comment period:* April 5, 2024.

ADDRESSES: The *Common Formats for Surveillance—Hospital Version 1.0* can be accessed electronically at the following website: *https://www.psoppc.org/psoppc_web/publicpages/surveillancecommonformats.*

FOR FURTHER INFORMATION CONTACT: Dr. Hamid Jalal, Center for Quality Improvement and Patient Safety, AHRQ, 5600 Fishers Lane, Rockville, MD 20857; Telephone (toll free): (866) 403–3697; Telephone (local): (301) 427–1111; TTY (toll free): (866) 438–7231; TTY (local): (301) 427–1130; Email: *pso@ahrq.hhs.gov.*

SUPPLEMENTARY INFORMATION:

Background on Common Formats Development

The Patient Safety and Quality Improvement Act of 2005, 42 U.S.C. 299b–21 to 299b–26, (Patient Safety Act) and the related Patient Safety and Quality Improvement Final Rule, 42 CFR part 3 (Patient Safety Rule), published in the **Federal Register** on November 21, 2008, 73 FR 70731–70814, provide for the formation of Patient Safety Organizations (PSOs), which collect and analyze confidential and privileged information regarding the quality and safety of health care delivery that meets the definition of PSWP. Aggregation of these data enables PSOs and others to identify and address underlying causal factors of patient safety and quality issues.

The Patient Safety Act provides for the development of standardized reporting formats using common language and definitions (Common Formats) to ensure that health care quality and patient safety data collected by PSOs and other entities are comparable. The Common Formats facilitate aggregation of comparable data at local, PSO, regional and national levels. In addition, the formats are intended to enhance the reporting of information that is standardized both clinically and electronically.

AHRQ has developed Common Formats for Event Reporting for three settings of care—acute care hospitals, nursing homes, and community pharmacies—as well as for diagnostic safety events across all care settings. AHRQ-listed PSOs are required to collect patient safety work product in a standardized manner to the extent practical and appropriate; this is a requirement the PSO can meet by collecting such information using Common Formats. Additionally, providers and other organizations not working with an AHRQ-listed PSO can use the Common Formats in their work to improve quality and safety; however, they cannot benefit from the Federal confidentiality and privilege protections of the Patient Safety Act.

Since February 2005, AHRQ has convened the Federal Patient Safety Work Group (PSWG) to assist AHRQ in developing and maintaining the Common Formats. The PSWG includes major health agencies within HHS as well as the Departments of Defense and Veterans Affairs. The PSWG helps assure the consistency of definitions/formats with those of relevant government agencies. In addition, AHRQ solicit comments from the private and public sectors regarding proposed versions of the Common Formats through the Patient Safety Organization Privacy Protection Center (PSOPPC). After receiving comments, the PSOPPC will solicit review of the formats by its Common Formats Expert Panel. Subsequently, PSOPPC will review this input and provide its feedback to AHRQ who then uses it to refine the Common Formats.

For the Common Formats, it should be noted that AHRQ uses the term ''surveillance'' in this context to refer to the improved detection of events and calculation of adverse event rates in populations reviewed that will allow for collection of comparable performance data over time and across populations of patients. These formats are designed to provide, through retrospective review of medical records, information that is complementary to that derived from event reporting systems.

AHRQ is specifically interested in receiving feedback in order to guide the improvement of the formats. The draft Event Descriptions for the *Common Formats for Surveillance—Hospital Version 1.0* are available at: *https://www.psoppc.org/psoppc_web/publicpages/surveillancecommonformats.* Comments on the *Common Formats for Surveillance—Hospital Version 1.0* can be submitted through: *https://www.psoppc.org/psoppc_web/publicpages/openforcomment.*

Additional information about the Common Formats can be obtained through AHRQ's PSO website: *https://pso.ahrq.gov/common-formats.*

Dated: March 1, 2024.

Marquita Cullom,

Associate Director.

[FR Doc. 2024–04767 Filed 3–5–24; 8:45 am]

BILLING CODE 4160–90–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Meeting of the Community Preventive Services Task Force (CPSTF)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: The Centers for Disease Control and Prevention, within the Department of Health and Human Services, announces the next meeting of the Community Preventive Services Task Force (CPSTF) on April 17–18, 2024.

DATES: The meeting will be held on Wednesday, April 17, 2024, from 9 a.m. to 5 p.m. EDT, and Thursday, April 18, 2024, from 9 a.m. to 5 p.m. EDT.

ADDRESSES: The meeting will be available to the public via web conference.

FOR FURTHER INFORMATION CONTACT: Kenya Turner, Office of Science, Office of Scientific Evidence and Recommendations, Community Guide Program; Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS–H21–10, Atlanta, GA 30329. Telephone: (404) 718–4592; Email: *CPSTF@cdc.gov.*

SUPPLEMENTARY INFORMATION:

Meeting Accessibility: The CPSTF meeting will be shown via web conference.

All meeting attendees must register by April 10, 2024. CDC will email web

conference login information and the agenda to registrants from the *CPSTF@cdc.gov* mailbox approximately two weeks before the meeting start date.

To register for the meeting, individuals should send an email to *CPSTF@cdc.gov* and include the following information: name, title, organization name, organization address, phone, and email.

Public Comment: Individuals who would like to make public comments during the April meeting must state their desire to do so in an email to the *CPSTF@cdc.gov* mailbox no later than April 10, 2024. The request should include name, organizational affiliation, and topic to be addressed. Public comment must be relevant to one of the topics proposed for the meeting. The requestor will receive instructions related to the public comment process for this meeting after the request is received. A public comment period follows the CPSTF's discussion of each systematic review and will be limited to no more than three minutes per person. Public comments may be used to inform task force discussions and will be included in the meeting summary.

Background on the CPSTF: The CPSTF is an independent, nonfederal panel whose members are appointed by the CDC Director. CPSTF members represent a broad range of research, practice, and policy expertise in prevention, wellness, health promotion, and public health. The CPSTF was convened in 1996 by HHS to identify community preventive programs, services, and policies that increase health and longevity, save lives and dollars, and improve Americans' quality of life. CDC is mandated to provide ongoing administrative, research, and technical support for the operations of the CPSTF. During its meetings, the CPSTF considers the findings of systematic reviews of existing research and practice-based evidence, and issues recommendations. CPSTF recommendations are not mandates for compliance or spending. Instead, they provide information about evidence-based options that decision makers and affected community members can consider when they are determining what best meets the specific needs, preferences, available resources, and constraints of their jurisdictions and constituents. The CPSTF's recommendations, along with the systematic reviews of the evidence on which they are based, are compiled on the Community Guide website (*www.thecommunityguide.org*).

Matters proposed for discussion: The agenda will consist of deliberation on systematic reviews of literature. Topics proposed for the April 2024 meeting include substance use, public health emergency preparedness and response, oral health, and social determinants of health. Changes regarding the start and end times for each day, and any updates to agenda topics, will be available on the Community Guide website (*www.thecommunityguide.org*) closer to the date of the meeting.

The meeting agenda is subject to change without notice.

Noah Aleshire,

Chief Regulatory Officer, Centers for Disease Control and Prevention.

[FR Doc. 2024–04779 Filed 3–5–24; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket No. CDC–2024–0017]

Human West Nile Virus Vaccine Meeting and Request for Information

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of public teleconference and request for information.

SUMMARY: The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), is announcing a meeting and opportunity to comment on a human West Nile virus (WNV) vaccine. The primary purpose of the meeting is to inform critical next steps toward the deployment of a human WNV vaccine.

DATES: The meeting will be held on April 5, 2024, from 8 a.m. to 5 p.m., eastern time.

Written comments must be received on or before April 4, 2024.

ADDRESSES: You may submit written comments, identified by docket number CDC–2024–0017, by either of the following two methods listed below. CDC does not accept comments by email.

- *Federal eRulemaking Portal: http://www.regulations.gov.* Follow the instructions for submitting comments.
- *Mail:* Randall Nett, MD, MPH, Centers for Disease Control and Prevention, 3156 Rampart Road, MS P02, Fort Collins, CO 80521.

Instructions: All information received in response to this notice must include the agency name and docket number [CDC–2024–0017]. All relevant comments received will be posted without change to *http://www.regulations.gov,* including any personal information provided. This will be an in-person and virtual meeting with a limited number of available Zoom lines. The in-person gathering will be by invitation only and held at Constitution Center, 400 7th St. SW, Washington, DC.

Accessibility: For information on access or services for individuals with disabilities, or to request accommodations for a disability, please contact Shawna Zuck by email at *wnv.vaccine@cdc.gov,* or by phone at (970) 221–6400, preferably at least 10 days before the meeting to allow as much time as possible to process your request.

FOR FURTHER INFORMATION CONTACT: Randall J. Nett, MD MPH, Chief, Arboviral Diseases Branch, 3156 Rampart Road, MS P02, Fort Collins, CO 80521; telephone number: (970) 221–6400; email address *wnv.vaccine@cdc.gov.*

SUPPLEMENTARY INFORMATION:

Background: WNV is a disease spread by mosquitoes that continues to cause illness and deaths each year in the United States and other areas of the world. Current mosquito control measures have been unsuccessful at decreasing the number of WNV disease cases. An approved human WNV vaccine could reduce the public health impact of WNV disease.

Purpose: The primary purpose of the meeting and public comment period is to inform critical next steps toward the development of a human WNV vaccine that is approved for use.

Attending the meeting: The meeting will be open to the general public. The meeting agenda and information on how to register for and attend the meeting online will be provided on request. If interested in attending the meeting online, please email *wnv.vaccine@cdc.gov.* This meeting is open to the public, limited only by the number of Zoom lines. The Zoom line will accommodate up to 500 participants and be available on a first come-first serve basis.

Public Participation

Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on *https://www.regulations.gov.* Therefore, do not include any information in your comment or